Forbes: New Study Supports MDMA As A Treatment For PTSD

Summary: Forbes publishes an overview of the announcement surrounding a successful confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD). “The Phase 3 confirmatory results support the development of MDMA-assisted therapy as a potentially new breakthrough therapy to treat individuals with PTSD—a patient population that is often left to suffer for years,” says Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC).

Originally appearing here (Archived)